Creating a new antibiotic to fight drug-resistant infections
Development of a Dual-Targeting ClpP Activating Antibiotic
This study is working on a new type of antibiotic that helps fight tough infections caused by certain bacteria, like MRSA and VRE, which don't respond well to current treatments, by making the bacteria break down their own proteins, so it can reach those hard-to-treat germs.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Arietis NIH-funded |
| Lab location | 1 site (Boston, UNITED STATES) |
| Project ID | NIH-10915576 on NIH RePORTER |
What this research studies
This research focuses on developing a novel ureadepsipeptide antibiotic (UDEP) aimed at treating infections caused by Gram-positive bacteria, which are increasingly resistant to existing antibiotics. The approach involves a unique mechanism that prompts bacteria to digest their own proteins, allowing the antibiotic to target dormant and biofilm-associated bacteria that traditional treatments cannot affect. The project specifically targets serious drug-resistant threats identified by the CDC, including MRSA and VRE, with the goal of advancing a promising candidate for future human trials.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with infections caused by drug-resistant Gram-positive bacteria, such as those with bacteremia or pneumonia.
Not a fit: Patients with infections caused by Gram-negative bacteria or those who do not have antibiotic-resistant infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients suffering from difficult-to-treat bacterial infections.
How similar studies have performed: Previous research has shown promise in developing antibiotics with novel mechanisms, indicating potential for success in this area.
Where this research is happening
Boston, UNITED STATES
- Arietis — Boston, United States (Active)
Researchers
- Principal investigator: Lafleur, Michael — Arietis
- Study coordinator: Lafleur, Michael
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.